Filtered By:
Source: Clinical Cancer Research
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 104 results found since Jan 2013.
Antibody-mediated delivery of anti-KRAS-siRNA in vivo overcomes therapy resistance in colon cancer.
Conclusions:The coupling of siRNA against KRAS to anti-EGFR antibodies provides a novel therapy approach for KRAS-mutated EGFR-positive cancer cells in vitro and in vivo. These findings provide an innovative approach for cancer specific siRNA application and for enhanced therapeutic potential of monoclonal antibody therapy and personalized treatment of cancer entities.
PMID: 25589625 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - January 14, 2015 Category: Cancer & Oncology Authors: Baeumer S, Baeumer N, Appel N, Terheyden L, Fremerey J, Schelhaas S, Wardelmann E, Buchholz F, Berdel WE, Müller-Tidow C Tags: Clin Cancer Res Source Type: research
siRNA lipid nanoparticle potently silence clusterin and delay progression when combined with androgen receptor co-targeting in enzalutamide resistant prostate cancer.
CONCLUSIONS: LNP siRNA can silence target genes in vivo and enable inhibition of traditionally non-druggable genes like CLU and other promising co-targeting approaches in ENZ-R CRPC therapeutics.
PMID: 26106075 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - June 23, 2015 Category: Cancer & Oncology Authors: Yamamoto Y, Lin PJ, Beraldi E, Zhang F, Kawai Y, Leong J, Katsumi H, Fazli L, Fraser R, Cullis PR, Gleave ME Tags: Clin Cancer Res Source Type: research
Targeted Nanomedicine for Suppression of CD44 and Simultaneous Cell Death Induction in Ovarian Cancer: an Optimal Delivery of siRNA and Anticancer Drug.
CONCLUSION: We show a high therapeutic potential for combinatorial treatment of ovarian carcinoma with a novel drug delivery system that effectively transports siRNA targeting to CD44 mRNA simultaneously with cytotoxic agents.
PMID: 24036854 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - September 13, 2013 Category: Cancer & Oncology Authors: Shah V, Taratula O, G OB, Taratula OR, Rodriguez-Rodriguez L, Minko T Tags: Clin Cancer Res Source Type: research
Functional precision medicine identifies novel druggable targets and therapeutic options in head and neck cancer.
CONCLUSIONS: High-throughput phenotyping with siRNA and drug libraries using patient derived tumor cells prioritizes mutated driver genes and identifies novel drug targets not revealed by genomic profiling. Functional profiling is a promising adjunct to DNA sequencing for precision oncology.
PMID: 29599409 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - March 29, 2018 Category: Cancer & Oncology Authors: Xu C, Nikolova O, Basom R, Mitchell RM, Shaw R, Moser R, Park H, Gurley KE, Kao M, Green CL, Schaub FX, Diaz RL, Swan HA, Jang IS, Guinney J, Gadi VK, Margolin AA, Grandori C, Kemp CJ, Méndez E Tags: Clin Cancer Res Source Type: research
Enhancing chemotherapy response with sustained EphA2 silencing using multistage vector delivery.
CONCLUSIONS: These findings indicate that MSV/EphA2 merits further development as a novel therapeutic agent for ovarian cancer.
PMID: 23386691 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - February 5, 2013 Category: Cancer & Oncology Authors: Shen H, Rodriguez-Aguayo C, Xu R, Gonzalez-Villasana V, Mai J, Huang Y, Zhang GD, Guo X, Bao L, Guoting Q, Deng X, Li Q, Erm D, Sakamoto JH, Liu X, Chavez-Reyes A, Han HD, Sood AK, Ferrari M, Lopez-Berestein G Tags: Clin Cancer Res Source Type: research
Inhibition of protein phosphatase 2A radiosensitizes pancreatic cancers by modulating CDC25C/CDK1 and homologous recombination repair.
CONCLUSIONS: Collectively, our data demonstrate that PP2A inhibition radiosensitizes pancreatic cancer both in vitro and in vivo via activation of CDC25C/CDK1 and inhibition of HRR, and provide proof-of-concept evidence that PP2A is a promising target for the improvement of local therapy in pancreatic cancer.
PMID: 23780887 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - June 18, 2013 Category: Cancer & Oncology Authors: Wei D, Parsels L, Karnak D, Davis M, Parsels J, Zhao LL, Maybaum J, Lawrence T, Sun Y, Morgan MA Tags: Clin Cancer Res Source Type: research
Ponatinib shows potent antitumor activity in small cell carcinoma of the ovary hypercalcemic type (SCCOHT) through multi-kinase inhibition.
CONCLUSION: Ponatinib is an effective agent for SMARCA4-mutant SCCOHT in both in vitro and in vivo preclinical models through its inhibition of multiple kinases. Clinical investigation of this FDA-approved oncology drug in SCCOHT is warranted.
PMID: 29440177 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - February 9, 2018 Category: Cancer & Oncology Authors: Lang JD, Hendricks WPD, Orlando KA, Yin H, Kiefer J, Ramos P, Sharma R, Pirrotte P, Raupach EA, Sereduk C, Tang N, Liang WS, Washington M, Facista SJ, Zismann VL, Cousins EM, Major MB, Wang Y, Karnezis AN, Sekulic A, Hass R, Vanderhyden BC, Nair P, Weissm Tags: Clin Cancer Res Source Type: research
Functional analysis of genes in regions commonly amplified in high-grade serous and endometrioid ovarian cancer.
CONCLUSIONS: By taking this integrative approach to target discovery we have streamlined the translation of high-resolution genomic data into pre-clinical in vitro studies, resulting in the identification of a number of genes that may be specifically targeted for the treatment of ovarian tumors.
PMID: 23362323 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - January 29, 2013 Category: Cancer & Oncology Authors: Davis SJ, Sheppard KE, Pearson RB, Campbell IG, Gorringe KL, Simpson K Tags: Clin Cancer Res Source Type: research
RRM2 Regulates Bcl-2 in Head and Neck and Lung Cancers: A Potential Target for Cancer Therapy.
CONCLUSIONS: Our novel findings add to the knowledge of RRM2 in regulating expression of the anti-apoptotic protein Bcl-2 and reveal a critical link between RRM2 and Bcl-2 in apoptosis signaling.
PMID: 23719266 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - May 29, 2013 Category: Cancer & Oncology Authors: Rahman MA, Amin AR, Wang D, Koenig L, Nannapaneni S, Chen Z, Wang Z, Sica GL, Deng X, Chen ZG, Shin DM Tags: Clin Cancer Res Source Type: research
HIF-1α of bone marrow endothelial cells implies relapse and drug resistance in patients with multiple myeloma and may act as a therapeutic target.
CONCLUSIONS: The HIF-1α protein in MMECs may induce angiogenesis and resistance to bortezomib and lenalidomide and be a plausible target for the antiangiogenic management of well defined relapsed/refractory MM patients. It may also have prognostic significance.
PMID: 24297864 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - December 2, 2013 Category: Cancer & Oncology Authors: Ria R, Catacchio I, Berardi S, De Luisi A, Caivano A, Piccoli C, Ruggieri V, Frassanito MA, Ribatti D, Nico B, Annese T, Ruggieri S, Guarini A, Minoia C, Ditonno P, Angelucci E, Derudas D, Moschetta M, Dammacco F, Vacca A Tags: Clin Cancer Res Source Type: research
Deoxycytidine kinase expression underpins response to gemcitabine in bladder cancer.
Conclusions:Gemcitabine resistance in bladder cancer cell lines was associated with decreased dCK expression, but gemcitabine-resistant xenografts were responsive to combination low-dose gemcitabine/IR. We propose that dCK activity in tumour vasculature renders it gemcitabine-sensitive, which is sufficient to invoke a tumour response and permit tumour cell kill in gemcitabine-resistant tumours.
PMID: 25224279 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - September 15, 2014 Category: Cancer & Oncology Authors: Kerr M, Scott H, Groselj B, Stratford M, Karaszi K, Sharma N, Kiltie AE Tags: Clin Cancer Res Source Type: research
HDAC inhibition overcomes acute resistance to MEK inhibition in BRAF mutant colorectal cancer by down-regulation of c-FLIPL.
CONCLUSIONS: Our findings indicate that c-MET/STAT3-dependent upregulation of c-FLIPL expression is an important escape mechanism following MEKi treatment in BRAFMT CRC. Thus, combinations of MEKi with inhibitors of c-MET or c-FLIP (eg. HDAC inhibitors) could be potential novel treatment strategies for BRAFMT CRC.
PMID: 25813020 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - March 26, 2015 Category: Cancer & Oncology Authors: Carson R, Celtikci B, Fenning CS, Javadi A, Crawford N, Perez-Carbonell L, Lawler M, Longley DB, Johnston PG, Van Schaeybroeck S Tags: Clin Cancer Res Source Type: research
Systematic screening identifies dual PI3K and mTOR inhibition as a conserved therapeutic vulnerability in osteosarcoma.
CONCLUSIONS: The approaches described here have identified dual inhibition of the PI3K/mTOR pathway as a sensitive, druggable target in OS and provide rationale for translational studies with these agents.
PMID: 25862761 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - April 10, 2015 Category: Cancer & Oncology Authors: Gupte A, Baker E, Wan SS, Stewart E, Loh A, Shelat AA, Gould CM, Chalk A, Taylor S, Lackovic K, Karlstrom A, Mutsaers A, Desai J, Madhamshettiwar PB, Zannettino AC, Burns C, Huang DC, Dyer M, Simpson KJ, Walkley C Tags: Clin Cancer Res Source Type: research
Cervical cancer stem cells selectively overexpress HPV oncoprotein E6 that controls stemness and self renewal through upregulation of HES1.
CONCLUSIONS: Our findings suggest the possible mechanism by which HPVE6 potentially regulate and maintain stem-like cancer cells through Hes1.
PMID: 26988248 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - March 17, 2016 Category: Cancer & Oncology Authors: Das BC, Tyagi A, Vishnoi K, Mahata S, Verma G, Srivastava Y, Masaldan S, Roy BG, Bharti AC Tags: Clin Cancer Res Source Type: research
HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer.
Conclusion: HER2 reactivation through acquisition of the HER2L755S mutation was identified as a mechanism of acquired resistance to L-containing HER2-targeted therapy in preclinical HER2-amplified breast cancer models, which can be overcome by irreversible HER1/2 inhibitors.
PMID: 28487443 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - May 9, 2017 Category: Cancer & Oncology Authors: Xu X, De Angelis C, Burke KA, Nardone A, Hu H, Qin L, Veeraraghavan J, Sethunath V, Heiser LM, Wang NJ, Ng CKY, Chen E, Renwick A, Wang T, Nanda S, Shea M, Mitchell T, Rajendran M, Waters I, Zabransky DJ, Scott KL, Gutierrez C, Nagi C, Geyer FC, Chamness Tags: Clin Cancer Res Source Type: research
